Impact of Drug-Eluting Stents on Revascularization Choices in Patients with Acute Coronary Syndromes and Multivessel Coronary Disease: Results from the.

Slides:



Advertisements
Similar presentations
Decline in the Use of Drug-Eluting Stents for Patients With NSTEMI Undergoing PCI: Results From the CRUSADE and ACTION Registries Matthew T. Roe, Christopher.
Advertisements

What Have We Learned from the CRUSADE Registry
Sumeet Subherwal, Richard G. Bach, Anita Y. Chen, Brian F. Gage, Sunil V. Rao, Tracy Y. Wang, W. Brian Gibler, E. Magnus Ohman, Matthew T. Roe, Eric D.
Connie N. Hess, MD, Bimal R. Shah, MD, MBA, S. Andrew Peng, MS, Laine Thomas, PhD, Matthew T. Roe, MD, MHS, Eric D. Peterson, MD, MPH Relationship of Early.
Clinical Trial Results. org Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation Eric Eisenstein, DBA; Kevin Anstrom,
ISAR-REACT 2 ESC 2007 M. Seyfarth, A. Kastrati, J. Mehilli, F.-J. Neumann, J. ten Berg, O. Bruskina, F. Dotzer, J. Pache, J. Dirschinger, P. B. Berger,
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
FFR vs Angiography for Multivessel Evaluation
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
Factors influencing treatment decisions for coronary artery disease after cardiac catheterization American Heart Association November 18, 2013 Dallas,
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
CRUSADE: A National Quality Improvement Initiative CRUSADE: A National Quality Improvement Initiative Can Rapid Risk Stratification of Unstable Angina.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
Preservation Solutions, Vein Graft Patency, and Outcomes after Coronary Bypass Surgery RE Harskamp, JH Alexander, PJ Schulte, CM Brophy, MJ Mack, ED Peterson,
Hamon M 1, Nienaber C 2, Galli S 3, Huber K 4, Gulba D 5, Hill J 6, Lafont A 7, Cequier A 8, Bernstein D 9, Deliargyris E 9 Institutions: 1. Centre Hospitalier.
STRIVE TM What Is the Evidence That Critical Pathways Work? UCLA Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) ACC Guidelines Applied.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
Background Current guideline recommend an early invasive strategy for NSTEMI patients (Class IIA). However, 67% US hospitals have no catheterization capability.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.
Alexandre Quadros, Dulce Welter, Fernanda Camozzatto, Áurea Chaves, Rajendra Mehta, Carlos Gottschall, Renato D. Lopes Identifying Patients at Risk for.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
6/04 CRUSADE: A National Quality Improvement Initiative C an R apid Risk Stratification of U nstable Angina Patients S uppress AD verse Outcomes with E.
Presenter Disclosure Information DISCLOSURE INFORMATION: The following relationships exist related to this presentation Stock options None; Consults for.
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
David Hildick-Smith Sussex Cardiac Centre. Background to ARTS Previous POBA studies Meta-analysis 3300 patients 1660 CABG, 1710 PTCA Deaths 79 PCI vs.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Clinical Trial Results. org Characteristics, Management, and Outcomes of 5,557 Patients Age ≥90 Years With Acute Coronary Syndromes: Results From the CRUSADE.
6/9/2008 Comparative effectiveness reviews: methodological observations David B. Matchar, MD Professor of Medicine and Director, Center for Clinical Health.
Trends in the Quality of Care of Patients with Acute Myocardial Infarction: The National Registry of Myocardial Infarction from 1990 to 2006 Bimal R. Shah,
Impact of Prior Myocardial Infarction Among Patients with Acute Myocardial Infarction Treated in Contemporary Practice: A Report from the ACTION Registry.
GUSTO IV ACS: Trial Design Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: – ST  > 0.5 mm or – elevated.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2:ARMYDA-2:
Multivessel Coronary Artery Disease
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
On behalf of J. Belardi, M. Leon, L. Mauri,
American College of Cardiology Presented by Dr. Stephan Windecker
The Time Dependence of Anti-thrombin Initiation in Patients with Non-ST-segment –elevation Acute Coronary Syndrome: Subgroup Analysis form the ACUITY.
2006 CRUSADE 2nd Quarter Results
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
(p = 0.32 for noninferiority)
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Maintenance of Long-Term Clinical Benefit with
Atlantic Cardiovascular Patient Outcomes Research Team
Presentation transcript:

Impact of Drug-Eluting Stents on Revascularization Choices in Patients with Acute Coronary Syndromes and Multivessel Coronary Disease: Results from the CRUSADE Quality Improvement Initiative Gogo PB, Dauerman HL, Mulgund J, Ohman EM, Gibler WB, Patel MR, Harrington RA, Peterson ED, and Roe MT for the CRUSADE investigators

AcknowledgementAcknowledgement n CRUSADE is a National Quality Improvement Initiative of the Duke Clinical Research Institute. CRUSADE is funded by Schering Corporation. The Bristol-Myers Squibb/Sanofi-Aventis Pharmaceuticals Partnership provides additional funding support. Millennium Pharmaceuticals also provided funding for this study.

DisclosuresDisclosures PB Gogo 1, HL Dauerman 1, J Mulgund 1, MR Patel 1, EM Ohman 2, WB Gibler 2, RA Harrington 2, ED Peterson 2, MT Roe 2,3 1 None 2 Millennium Pharmaceuticals, Inc.; Bristol-Myers Squibb/Sanofi- Aventis Pharmaceuticals Partnership; Schering Corporation; Significant, Research Grants 3 Millennium Pharmaceuticals, Inc.; Bristol-Myers Squibb/Sanofi- Aventis Pharmaceuticals Partnership; Schering Corporation; Significant, Speakers Bureau

BackgroundBackground n CRUSADE is a national quality improvement initiative involving > 500 U.S. hospitals; it is designed to improve the care of high-risk patients with non–ST-segment elevation acute coronary syndromes. n Approximately 80% of U.S. patients receive DES during PCI. n Recent registry data (ARTS II) suggests that PCI with DES may be a reasonable alternative to CABG surgery for patients with multivessel CAD n CRUSADE is a national quality improvement initiative involving > 500 U.S. hospitals; it is designed to improve the care of high-risk patients with non–ST-segment elevation acute coronary syndromes. n Approximately 80% of U.S. patients receive DES during PCI. n Recent registry data (ARTS II) suggests that PCI with DES may be a reasonable alternative to CABG surgery for patients with multivessel CAD

Study Objectives n To characterize temporal trends in the use of PCI vs. CABG vs. medical therapy in all NSTE acute coronary syndrome patients since the introduction of DES n To characterize temporal trends in the use of PCI vs. CABG vs. medical therapy for NSTE ACS patients with 3-vessel CAD since the introduction of DES n To characterize temporal trends in the use of PCI vs. CABG vs. medical therapy in all NSTE acute coronary syndrome patients since the introduction of DES n To characterize temporal trends in the use of PCI vs. CABG vs. medical therapy for NSTE ACS patients with 3-vessel CAD since the introduction of DES

Inclusion Criteria for CRUSADE n Ischemic symptoms lasting  10 minutes within 24 hours and at least one of the following: n Positive cardiac markers l CK-MB or TnI / TnT above ULN l Positive bedside troponin assay n Dynamic ST-segment ECG changes: l ST-segment depression  0.5 mm l Transient ST-segment elevation  1 mm (lasting < 30 mins) n Ischemic symptoms lasting  10 minutes within 24 hours and at least one of the following: n Positive cardiac markers l CK-MB or TnI / TnT above ULN l Positive bedside troponin assay n Dynamic ST-segment ECG changes: l ST-segment depression  0.5 mm l Transient ST-segment elevation  1 mm (lasting < 30 mins)

Analysis Population n = 148,147 n = 103,288 n = 25,068 All patients in CRUSADE Initiative From Jan to June 2005 Patients were excluded at hospitals without both PCI/CABG capability as well as if they had contraindications to catheterization  Overall revascularization analysis Subgroup of patients with three vessel CAD  3-vessel CAD revascularization analysis

Data Collection and Data Analysis n Sites participate in a retrospective chart review for in-hospital medications, procedures, and outcomes. n Temporal trends for the use of revascularization versus medical therapy in all patients were measured. n Factors associated with use of PCI vs. CABG for patients with 3-vessel CAD were determined by logistic regression analysis. n Sites participate in a retrospective chart review for in-hospital medications, procedures, and outcomes. n Temporal trends for the use of revascularization versus medical therapy in all patients were measured. n Factors associated with use of PCI vs. CABG for patients with 3-vessel CAD were determined by logistic regression analysis.

Results for All Patients: 103,288 Patients with High Risk NSTE Acute Coronary Syndromes

Temporal Trends in the Use of Revascularization Among All Patients PeriodCABG SurgeryPCIMedical Therapy Jan-Mar %38.3%48.9% Apr-Jun %39.8%47.0% Jul-Sep %40.2%46.2% Oct-Dec %40.0%45.7% Jan-Mar %39.7%47.5% Apr-Jun %39.9%48.0% Jul-Sep %41.1%46.3% Oct-Dec %50.2%35.9% Jan-Mar %50.8%34.5% Apr-Jun %53.2%32.8% Jul-Sep %52.6%34.3% Oct-Dec %53.3%33.2% Jan-Mar %53.2%33.5% Apr-Jun %52.5%35.5% Drug-eluting stents Approved by FDA p for trend in CABG surgery is not significant

Temporal Trends in Type of Revascularization Strategy in All Patients: PCI vs. CABG p for trend <0.01 PeriodCABG SurgeryPCI Jan-Mar %74.9% Apr-Jun %75.1% Jul-Sep %74.7% Oct-Dec %73.7% Jan-Mar %75.6% Apr-Jun %76.6% Jul-Sep %76.6% Oct-Dec %78.3% Jan-Mar %77.5% Apr-Jun %79.2% Jul-Sep %80.1% Oct-Dec %79.8% Jan-Mar %80.0% Apr-Jun %81.5% Drug-eluting stents Approved by FDA

A Significant Reduction in the Use of Medical Therapy Alone Among All Patients

Sub-Group Analysis (N=25,068): Patients with 3-Vessel Coronary Artery Disease

Use of Drug-Eluting Stents in CRUSADE * Kandzari, AJC, *

Baseline Characteristics of Patients Over Time: 3-Vessel Coronary Artery Disease Overall n=25,036 Before DES n=8583 After DES n=16,485 P Age, y, median Female30.5%31.4%30.1%0.05 White83.7%83.6%83.8%0.07 Diabetes mellitus38.4%38.9%38.1%0.42 Renal insufficiency12.1%12.0%12.2%0.61 Hypertension73.3%72.9%73.5%0.35 Dyslipidemia57.9%56.0%58.9%<0.01 Smoking27.8% 27.9%0.99 Prior CABG30.4%30.1%30.6%0.61 Prior PCI24.0%24.4%23.7%0.12 Prior Stroke9.9%9.7%9.9%0.71 Prior MI33.7%35.3%32.8%<0.01 Prior CHF14.3%14.8%14.1%0.10

Clinical Presentation of Patients Over Time: 3-Vessel Coronary Artery Disease Before DES n=8583After DES n=16,485P CHF at presentation21.7%22.2%0.53 Positive cardiac markers89.9%92.2%<0.01 ST depression41.7%37.5%<0.01 Transient ST elevation7.0%6.1%<0.01

Temporal Trends in Revascularization and Medical Therapy Among Patients with 3-Vessel CAD PeriodCABG SurgeryPCIMedical Therapy Jan-Mar %36.9%27.9% Apr-Jun %36.2%24.7% Jul-Sep %34.6%26.7% Oct-Dec %34.0%26.4% Jan-Mar %37.2%28.0% Apr-Jun %34.4%29.6% Jul-Sep %38.0%25.3% Oct-Dec %40.7%24.6% Jan-Mar %36.7%25.8% Apr-Jun %39.0%25.8% Jul-Sep %41.2%26.9% Oct-Dec %40.9%26.0% Jan-Mar %42.4%25.4% Apr-Jun %44.8%25.5% Drug-eluting stents Approved by FDA p for trend in CABG surgery <0.01

The Use of Medical Therapy Alone in Patients With 3-Vessel CAD was Constant Over Time

Trends in Type of Revascularization Strategy for 3-Vessel CAD: PCI vs. CABG

Factors Associated with Use of PCI vs. CABG for 3-Vessel CAD (n=18,462) Changed after DES IntroductionAdjusted OR95% CI Prior CABG surgery, before DES Prior CABG surgery, after DES Unchanged after DES Introduction Previous PCI Male ST-depression (vs. none) Transient ST-elevation (vs. none) Cardiology Inpatient Care Academic Hospital Renal Insufficiency Previous history of CHF Family history of CAD Hypertension CHF at presentation

Limitations n The reasons for use of revascularization strategies or medical therapy alone were not prospectively collected by sites. n Detailed angiographic characteristics were not collected; the influence of lesion type and severity on revascularization decisions could not be determined. n Long-term outcomes (including rates of stent thrombosis, death, and repeat revascularization) were not collected. n The reasons for use of revascularization strategies or medical therapy alone were not prospectively collected by sites. n Detailed angiographic characteristics were not collected; the influence of lesion type and severity on revascularization decisions could not be determined. n Long-term outcomes (including rates of stent thrombosis, death, and repeat revascularization) were not collected.

Conclusions (1) n The introduction of drug eluting stents has been associated with increased use of revascularization in all patients with NSTE ACS. n Among patients with 3-vessel coronary artery disease, PCI is now the predominant mode of revascularization. n The introduction of drug eluting stents has been associated with increased use of revascularization in all patients with NSTE ACS. n Among patients with 3-vessel coronary artery disease, PCI is now the predominant mode of revascularization.

Conclusions (2) n One-fourth of patients with 3-vessel coronary artery disease are still managed medically in current practice, and this proportion has not changed due to DES introduction. n Randomized trials are needed to determine the impact of PCI vs. CABG for patients with 3-vessel CAD. n One-fourth of patients with 3-vessel coronary artery disease are still managed medically in current practice, and this proportion has not changed due to DES introduction. n Randomized trials are needed to determine the impact of PCI vs. CABG for patients with 3-vessel CAD.